Captor Therapeutics SA

DUBLIN--( BUSINESS WIRE )--The "Global MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights 2023" report has been added to ResearchAndMarkets.com's offering. A compelling case has been made for the use of MCL-1 inhibitors in the treatment of cancer by the positive preclinical trial results of numerous other investigational candidates besides S63845. MCL-1 also has the potential to be used as a therapeutic target for a variety of malignancies, as evidenced by the outcomes of the expansion of these candidates to solid tumors. Research and development of MCL-1 inhibitors is still an emerging field, however, prominent pharmaceutical companies like Amgen, Novartis, and AstraZeneca have also invested in the development of these candidates, which vouches for the future potential of MCL-1 inhibitors and the unanticipated market growth in the coming years. There still remain certain drawbacks associated with MCL-1 inhibitors that need to be addressed to realize the prospective growth potential of the MCL-1 inhibitors market. MCL-1 has been identified as a central protein in the pathogenesis of several cancers, majorly hematopoietic malignancies. It is a dynamic and unique protein, which is involved in a variety of cellular functions, including cell cycle progression, metabolism, and differentiation among others. However, its role as a pro-survival member of the BCL-2 that prevents apoptosis is what has brought it into the limelight as a promising therapeutic target for cancer. In addition, overexpression of MCL-1 also promoted drug resistance of both solid tumors and hematological malignancies to various chemotherapeutic agents through different signaling mechanisms. Therefore, due to its key role in promoting cell survival and the resistance to treatment, MCL-1 has emerged as a promising therapeutic target, and researchers are now working to find strategies to inhibit MCL-1. Compared to other proteins, targeted inhibition of the MCL-1 has more advantages. The protein is overexpressed in a number of cancers including breast and lung cancers, two cancers having the highest incidence and mortality rates. MCL-1 can prevent the process of apoptosis in cancer cells and promote survival, leading to an increase in tumor mass. In preclinical trials, inhibition of the MCL-1 was shown to induce cell death. Additionally, it also increased the efficacy of other anticancer drugs administered in combination with the MCL-1 inhibitor. Further, MCL-1 is also indicated in the development of resistance to current treatments. Especially in blood cancers, resistance to treatment is a common event occurring in cancer patients and is something that has been challenging the treatment outcomes and survival of patients. Overexpression of MCL-1 plays a role in this as its upregulation can counteract the effects of drugs that induce apoptosis otherwise. Targeting the MCL-1 can overcome this resistance and enhance the effectiveness of chemotherapies used in treating hematopoietic cancers. Adding on to this, the combination of MCL-1 inhibitors with other targeted therapies and anticancer drugs can have a synergic effect on cancer cells, leading to enhanced cell death and improved treatment outcomes. Research has also found that while normal cells rely on several survival mechanisms, most cancer cells become highly dependent on MCL-1 for their survival. Therefore, it is hypothesized that targeting the MCL-1 will be a highly targeted strategy specific to cancer cells, and it will leave non-cancer cells unharmed. To some extent, results from clinical and preclinical trials conducted by researchers and drug developers have been able to justify this. Though there remain some limitations such as the emergence of unforeseen adverse effects such as cardiac problems, the potential of MCL-1 as a therapeutic target cannot be denied, and is an avenue that needs to be explored more with potential candidates. Results from preclinical and clinical trials for many promising candidates have returned encouraging outcomes. S63845 was among the first candidates to enter preclinical trials, and to date, it has been assessed in a number of solid and hematopoietic cancers and has shown promising results. Servier and Novartis jointly developed S64315/MIK665, the clinical-trial version of S63845. As mentioned above, MCL-1 inhibitors can act as ideal combinatorial agents. Therefore, S64315 is being assessed in combination with azacitidine, a chemotherapeutic drug, and VOB560, an investigational BCL-2 inhibitor, in patients with hematopoietic cancers. Report Highlights: Research Methodology ML1 Inhibitor Drug In Clinical Trials: > 12 Drugs Commercially Approved MCL1 Inhibitor Drug: 1 (Synribo) ML1 Inhibitor Drug Clinical Trials Insight By Company, Indication and Phase Global MCL1 Inhibitor Drug Market Opportunity Outlook MCL1 Inhibitor Drug Clinical Innovation and Development Trends By Different Cancers Key Topics Covered: 1. Research Methodology 2. Introduction To MCL1 Inhibitors 2.1 MCL1 as Therapeutic Target 2.2 Role of MCL1 in Cancer 3. MCL1 Inhibitors - Mechanism of Action 3.1 Indirect Inhibition of MCL1 3.2 Direct Inhibition of MCL1 4. MCL1 Inhibitor Drug Clinical Innovation by Indication 4.1 Leukemia 4.2 Lymphoma 4.3 Multiple Myeloma 4.4 Solid Cancers 4.4.1 Breast cancer 4.4.2 Lung Cancer 4.4.3 Melanoma 4.4.4 Colorectal cancer 5. Global MCL1 Inhibitor Drug Market Opportunity Outlook 5.1 Current Clinical Research Landscape 5.2 MCL1 Inhibitor Drug Future Commercialization Opportunities 6. Global MCL1 Inhibitor Drugs Clinical Trials Overview 6.1 By Company 6.2 By Country 6.3 By Indication 6.4 By Patient Segment 6.5 By Phase 7. Global MCL1 Inhibitor Drugs Clinical Trials Insight By Company, Indication & Phase 7.1 Preclinical 7.2 Phase-I 7.3 Phase-I/II 7.4 Phase-II 8. Marketed MCL1 Inhibitor Drug Clinical Insight 9. Competitive Landscape 9.1 Amgen 9.2 Ascentage Pharma 9.3 Broad Institute 9.4 Captor Therapeutics 9.5 Cyclacel Pharmaceuticals 9.6 Gilead Sciences 9.7 Prelude Therapeutics 9.8 Servier 9.9 Sirnaomics 9.10 Teva Pharmaceutical Industries 9.11 University Of Innsbruck 9.12 Vernalis 9.13 Vichem Chemie For more information about this report visit https://www.researchandmarkets.com/r/amza4p About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to planSolid cash position allows cash visibility until at least late 2024 aided by non-dilutive funding and a cost-efficient R&D structure WROCŁAW, Poland, May 30, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE: CTX), a biopharmaceutical company, specialized in the development of drugs based on Targeted Protein Degradation (TPD), today published its consolidated report for Q1 2023. In Q1 2023 Captor Therapeutics announced the next steps in the implementation of the Company’s 2023-25 strategy, aimed at becoming one of the global leaders in the TPD field.The Company also announced the new molecular targets its compounds are targeting and announced the latest research results from its lead projects CT-01, CT-02 and CT-05.The project carried out in cooperation with Ono Pharmaceutical Co. Ltd. is progressing according to schedule and both companies are highly satisfied with the results so far. "At the beginning of March 2023, thanks to the significant advances achieved in 2022 and early 2023 by our research teams, we announced our ambitious 2023-2025 plan that aims to transform Captor into a mid-clinical stage biotech company with proof of concept data in man for its lead asset CT-01 by the end of the period. We also took great strides forward with our OptigradeTM platform by generating several series of proprietary ligands to four different novel E3 Ligases that could form the basis of a new generation of degrader drugs. We look forward to leveraging this innovative discovery engine through additional partnerships that will develop additional skills within our team and provide additional non-dilutive funding," said Michał Walczak, CSO at Captor Therapeutics. Ono Pharmaceutical and Captor announced in November 2022 a drug discovery collaboration to develop small molecule protein degraders for the treatment of neurodegenerative diseases. This discovery collaboration progressed well in the first quarter, with an excellent level of collaboration between the two company teams and has already started to deliver its first promising results. "I am pleased to report that this collaboration is progressing extremely well and the initial data is confirming the validity of our approach. It is comforting to see that this important collaboration is demonstrating the high level of scientific quality and creativity of our team as we tackle the major issue of neurodegeneration in partnership with Ono Pharmaceutical," said Dr. Tom Shepherd, CEO at Captor Therapeutics. In Q1 2023, the Company also continued the extended cooperation with Sosei Heptares, focused on the discovery and development of new small molecules aimed at the degradation of G protein-coupled receptors. "From January to March 2023, we allocated nearly PLN 16 million to R&D activities, which is supported of non-dilutive funding of PLN 5,6 million which helped us maintain a stable capital position and reduce the need for financing. This non-dilutive funding has been a key benefit to Captor since its inception, in particular considering the challenging financing environment the global Biotech industry has faced over the last 18 months," indicated Radosław Krawczyk, CFO at Captor Therapeutics. About Captor TherapeuticsCaptor Therapeutics is a biopharmaceutical company specializing in the development of breakthrough drugs based on Targeted Protein Degradation (TPD) technology for the treatment of diseases with high unmet medical needs. TPD allows innovative approach to developing new drugs that can focus on the new molecular targets considered incurable using conventional methods of drug development and provide new treatment methods for diseases where existing drugs do not provide optimal therapeutic benefits. Captor is currently developing therapeutics for incurable, severe diseases, including malignancies and autoimmune diseases. For more information on Captor Therapeutics visit: http://www.captortherapeutics.com LinkedIn: @CaptorTherapeutics Twitter: @CaptorTherapeu1 Media and investor contacts: International Investor Relations: LifeSci AdvisorsGuillaume van Renterghem+41 (0)76 735 01 31gvanrenterghem@lifesciadvisors.com

CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancer Strong preclinical data generated with CT-02 against NEK7 CT-05 potential best-in-class pro high potential / partially de-risked PKCӨ protein pathway Webcast to take place on Thursday 30th March at 4 pm CET / 10 am ET – Registration link below WROCŁAW, Poland, March 28, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today discloses the identity of the drug targets as well as associated supporting data, and provides an update on the progress in the research and development of its pipeline lead programs CT-01, CT-02 and CT-05. Dr Michal Walczak, Chief Scientific Officer and Co-founder of Captor, will present the scientific rational for these targets as well as the market potential of each of Captor’s lead programs and will answer questions during a webcast on March 30th 2023. Webcast invitation to discuss scientific rational and market potential of new targets Date: March 30th 2023 at 4pm CET / 10 am ET Please register by following this link. CT-01 / CPT-6281 targeting GSPT1, SALL4 and (new disclosure) NEK7 CT-01 / CPT-6281 is currently undergoing IND/CTA-enabling studies with the first clinical trial expected to start at the end of 2023. The first indication will be in Hepatocellular Carcinoma (HCC). CPT-6281 is a first-in-class degrader of GSPT1, SALL4, and NEK7. GSPT1 is a protein involved in the termination of translation, SALL4 is a transcription factor often over-expressed in HCC patients and correlating with poor prognosis, and NEK7 is a protein in which degradation leads to a reduction in IL-1b production, a well-known pro-carcinogenic factor. Moreover, CPT-6281 is particularly well suited for liver, lung, and neuroendocrine tumors since it is a prodrug1 activated by an enzyme present in high concentration in the liver, the lungs, and some gastrointestinal tumors. CT-02 targeting (new disclosure) NEK7 In addition to the potential benefits of NEK7 degradation combined with the degradation of GSPT1 and SALL4 in cancer, as mentioned above for the CT- 01 Project, the selective degradation of NEK7 alone in the CT-02 Project has many potential benefits as a treatment of several autoimmune diseases. Such NEK7 degradation allows the modulation of the inflammasome, a complex that plays a critical role in the regulation of the inflammatory response. Captor believes that selective NEK7 degraders have the potential to overcome the limitations shown in the past of NLRP3 inhibitor drugs related to increased susceptibility to infection. Importantly, it is established that NEK7 pro-inflammatory activity is largely driven by its scaffolding function, and because of that, classical inhibition of NEK7’s kinase function doesn’t provide therapeutic benefit. It is therefore expected that selective degradation of NEK7 would also remove the NEK7 scaffolding function leading to potent inflammatory inhibition. Pre-clinical studies have revealed the following benefits of CT-02: Effective NEK7 degradation at low concentrations in vitro (high potency) and ex vivo Degradation of NEK7 is correlated with the desired in-vitro biological effects on the inflammatory response Optimised compounds with good pharmacokinetics in animals have been developed Compounds with the ability to cross the blood-brain-barrier have been identified and provide opportunity for further development in the area of neurodegeneration CT-05 targeting (new disclosure) PKCӨ (PKC theta) CT-05 targets the PKCӨ protein, a protein highly relevant in both autoimmune diseases and cancer. Indeed, PKCӨ plays an important role in the modulation of T cells by limiting the suppressive function of T cells. It is therefore expected that degrading the PKCӨ protein would lead to an increased T cell suppressive function. PKCӨ is a high-value target with opportunities in certain autoimmune diseases, such as allergy, psoriasis, and inflammatory bowel disease, as well as certain malignancies, such as breast and gastrointestinal cancer. Importantly, the approach behind CT-05 is partially de-risked thanks to: the PKCӨ protein acts via the CD3/CD28 – IL-2/IL-17 pathway. The IL-17 pathway is a clinically validated pathway in autoimmune diseases such as psoriasis with established modulators2 the potential of the PKCӨ protein pathway is underpinned by BMS’s latest in-licensing of Exscientia’s PKCӨ inhibitor EXC4318 In preclinical studies, CT-05 has demonstrated attractive features that differentiate CT-05 from inhibitors that failed in clinical trials due to side effects: Potent degradation and first-in-class selectivity pro the molecular target PKCӨ in immune cells in vitro Desired effect on ex vivo immune cells No effect on non-immune cells AboutCaptorTherapeutics Captor Therapeutics is a drug discovery and development company applying targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases with significant unmet medical need. TPD is a revolutionary approach to developing new drugs that can target new molecular targets considered undruggable" using classical drug modalities and provide additional treatment options for diseases where existing drugs do not provide optimal treatment. Captor is currently developing treatments for undertreated serious conditions, including cancer and autoimmune diseases. For more information on Captor Therapeutics, visit: LinkedIn: @CaptorTherapeutics Twitter: @CaptorTherapeu1 Mediaandinvestor contacts: PolishMediaandInvestorRelations: Point of View Bartosz Sawulski +48 694 400 787 captortherapeutics@pov.pl International InvestorRelations: LifeSci Advisors Guillaume van Renterghem +41 (0)76 735 01 31 gvanrenterghem@lifesciadvisors.com 1 A prodrug is a biologically inactive compound which can be metabolized in the body to produce a drug which is pharmacological active. 2 Ixekizumab, Secukinumab, Brodalumab